The therapeutic efficacy of radioiodine ( 131 I) therapy has been reported to be variable among cancer patients and even between metastatic regions in the same patients. Because the expression level of sodium iodide symporter (NIS) cannot reflect the efficacy of therapy, other strategies are required to predict the precise therapeutic effect of 131 I therapy. In this research, we investigated the correlation between iodine (I) uptake, apoptosis imaging, and therapeutic efficacy. Two HT29 cell lines, cytomegalovirus (CMV)-NIS (or NIS+++) and TERT-NIS (or NIS+), were established by retroviral transfection. I uptake was estimated by I-uptake assay and gamma camera imaging. Apoptosis was evaluated by confocal microscopy and a Maestro fluorescence imaging system (CRi Inc., Woburn, MA) using ApoFlamma (BioACTs, Seoul, Korea), a fluorescent dye-conjugated apoptosis-targeting peptide 1 (ApoPep-1). Therapeutic efficacy was determined by tumor size. The CMV-NIS showed higher I uptake and ApoFlamma signals than TERT-NIS. In xenograft models, CMV-NIS also showed high 99m technetium signals and ApoFlamma signals. Tumor reduction had a stronger correlation with apoptosis imaging signals than with gamma camera imaging signals, which reflect I uptake. Higher NIS-expressing tumors showed increased apoptosis and I uptake, resulting in a significant tumor reduction. Moreover, tumor reduction showed a strong correlation with ApoFlamma imaging compared to I-uptake imaging.
R ADIOIODINE (
131 I) has been effectively used in patients with differentiated thyroid carcinomas for more than 70 years. 1 The molecular mechanism behind iodine (I) uptake in cancer cells was mediated by the membrane protein sodium iodide symporter (NIS). As a consequence, the relationship between cellular NIS expression and the therapeutic effect of 131 I has been studied to improve the efficacy of 131 I therapy. 2, 3 The therapeutic effect of 131 I on residual/metastatic lesions of differentiated thyroid cancer patients is variable among patients. 4 For example, one-third of pulmonary metastases were cured in the Seoul National University Hospital, but 8% of the tumors showed aggressive characteristics. 5 NIS expression seems to provide important information on the therapeutic effect of 131 I.
However, NIS expression cannot currently successfully reflect the therapeutic efficacy of 131 I for various reasons, including insufficient thyroid-stimulating hormone stimulation or the failure of a low-I diet. [6] [7] [8] Consequently,
other strategies are required to predict the precise therapeutic effect of 131 I rather than relying on NIS expression. As apoptosis is an essential process in cancer therapy, 9 apoptosis imaging provides important prognostic information. 10 Although annexin V has been widely used for apoptosis imaging in clinical circumstances, annexin V, which targets phosphatidylserine in the inner leaflet of cell membrane, has many disadvantages in terms of a lack of specificity for apoptotic cells to nonapoptotic cells, slow removal from the body, and a low signal to background ratio for in vivo practice. 11, 12 ApoFlamma (BioActs, Seoul, Korea) is a new apoptosistargeting peptide 1, named ApoPep-1, with six amino acids (CQRPQR) conjugated to a fluorescent dye ( Figure S1 , online version only). ApoPep-1 targets apoptotic cells by binding to histone H1 exposed on the surface of apoptotic cells but does not compete with annexin V ( Figure S2 , online version only). 13 ApoFlamma was stable in serum and did not bind to either white or red blood cells. 14, 15 Unlike bulky annexin V, ApoFlamma shows efficient tissue penetration, rapid clearance from blood circulation, and low immunogenicity, making it a useful probe for in vitro and in vivo imaging. 16, 17 In the present study, a human colorectal adenocarcinoma cell line, transfected with two different retroviral NIS vectors that show different levels of NIS expression, underwent 131 I gene therapy. The correlations among I uptake, apoptosis and tumor size reduction were analyzed to predict the therapeutic efficacy of 131 I treatment in tumors expressing different levels of NIS.
Materials and Methods

Establishment of Cell Lines Expressing Different Levels of NIS
The human colorectal adenocarcinoma cell line (HT29) was obtained from the Korean Cell Line Bank (KCLB, Seoul, Korea) and infected with retrovirus having the TERT promoter (weak) or the CMV promoter (strong) 18 for differing degrees of NIS expression according to the manufacturer's instructions (BD Biosciences Clontech, Palo Alto, CA) ( Figure 1A ). Stable cells were isolated from puromycin selection (1.5 g/mL) and confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot ( Figure 1B ). The HT29 cell lines with higher NIS expression were labeled as CMV-NIS (or NIS+++) cells, whereas cell lines with lower NIS expression were labeled as TERT-NIS (or NIS+) cells. PCR primers for hNIS were ACTTTGCAGTACATTGTAGCC (sense), AC-AGTGACTGCAGCCATAG (antisense); b-actin TCTACA-ATGAGCTGCGTGTG (sense), TAGATGGGCACAGTG-TGGGT (antisense). Antibodies for hNIS (Abcam, Cambridge, MA) or b-actin (Cell Signaling, Danvers, MA) and antimouse antibody (Invitrogen-Molecular Probes, Eugene, OR) were used for Western blot. 
In
In Vitro Confocal Microscopy Imaging
Apoptosis was imaged by ApoFlamma fluorescence with confocal microscopy. Tumor cells were seeded in 24-well plates. Following 24 hours' incubation, cells were washed with HBSS once and incubated with 500 mL of HBSS containing 37 MBq (0.1 mCi) of 131 I and 20 mM NaI for 7 hours at 37uC to induce apoptosis. Cells were washed twice with HBSS and once with PBS. Cells were then incubated with 1 mL of ApoFlamma (648 mg/mL) for 1 hour. Cells were fixed with 3.7% formaldehyde, and the ApoFlamma fluorescent signals (FPR-648) were analyzed by the Zeiss LSM510 META confocal imaging system (Carl Zeiss, Thornwood, CA). Further analysis was performed by MetaMorph software (Molecular Probes, Portland, OR) and the immunofluorescent cell population analysis system (TissueFAXS, TissueGnostics, Vienna, Austria).
Tumor Xenograft in Nude Mice
All in vivo procedures were approved by the Institutional Animal Care and Use Committee of Seoul National University in accordance with the guidelines for the care and use of laboratory animals. Tumor cells were subcutaneously transplanted into 5-week-old adult male BALB/c nude mice weighing 20 g on average. The two different NIS-expressing tumor cells were transplanted in both the right (CMV-NIS) and left (TERT-NIS) thighs of each mouse. When tumor xenograft reached 10 mm in diameter, mice were treated with 131 I (1.6 mCi) to induce apoptosis.
Tumor Size Measurement
Tumor sizes were measured with calipers weekly and calculated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Tumor growth was reported as relative tumor size on the initial day of 131 I injection.
In Vivo Fluorescence Imaging
Mice were intraperitoneally injected with 100 mL of 131 I with 59.2 MBq (1.6 mCi). Three days later, mice were anesthetized with a solution containing 8 mg/mL ketamine (Ketalar, Panpharma, Fougères, France) and 0.8 mg/mL xylazine (Rompun, Bayer Pharma, Puteaux, France) at 0.01 mL/g body weight. The 100 mL of ApoFlamma (150 mg/mouse) was injected intravenously, and fluorescent images were acquired using a Maestro in vivo imaging system (CRi Inc., Woburn, MA). The fluorescent images were obtained using the red-filter set (a band-pass filter from 615 to 655 nm and a long-pass filter of 700 nm). The tunable filter was automatically moved in 10 nm increments from 615 to 655 nm, whereas the camera captured images at each wavelength using a constant exposure.
In Vivo Gamma Camera Imaging
To estimate the activity of NIS protein in tumor, gamma camera images were acquired before 131 I therapy. Tumorbearing mice were intraperitoneally injected with 22.2 MBq (0.6 mCi) of 99m technetium ( 99m Tc). Twenty minutes later, mice were anesthetized and scanned with a gamma camera (ON 410, Ohio Nuclear, Solon, OH) equipped with a pinhole collimator. A region of interest (ROI) was drawn over the target tumor margin, and every pixel within ROI was corrected by subtracting the background value, which was measured in the remote areas away from the mouse body.
Statistical Analysis
All experiments were repeated at least three times, and data are reported as mean 6 standard deviation. Statistical significance was determined by t-test using Microsoft Excel 2010.
Results
In Vitro I-Uptake Assay and ApoFlamma Imaging of Tumor Cells with Different NIS Expression 125 I-uptake assay revealed that the I-accumulating ability of the CMV-NIS cells was significantly higher than that of the TERT-NIS tumor cells ( Figure 1C ). In the TERT-NIS cells, there was no significant difference in cellular apoptosis between the measured by ApoFlamma imaging is positively related to NIS expression and I uptake. Interestingly, the cellular level of apoptosis measured by ApoFlamma seems to be quite heterogeneous.
In Vivo Gamma Camera Imaging and ApoFlamma Imaging of Tumors with Different NIS Expression
To evaluate the ability of 131 I uptake from tumors with different NIS expression, 99m Tc uptake was estimated by gamma camera imaging as an indicator of NIS activity ( Figure 3A) . From ROI of the two tumors drawn on gamma camera images, significantly more (1.9-fold) gamma radiation signal was observed in the CMV-NIS tumors compared to the TERT-NIS tumors. 
Discussion
In thyroid cancer patients, NIS expression and I uptake are key factors for radionuclide therapy as I uptake is positively correlated with therapeutic response. 5, 19 From the patients at Seoul National University Hospital over the past 25 years, NIS protein expression has been observed in metastatic lesions by immunostaining and compared to immunostaining after Because tumor response to the therapy varies at the single-cell level, tumor heterogeneity is considered an important factor for different therapeutic responses. 21 Human cancers show substantial tumor heterogeneity in distinguishable phenotypic features, such as cellular morphology, gene expression, metabolism, and differential sensitivity to therapeutic agents and radiation. 22 Although NIS expression in tumors is associated with the therapeutic response of 131 I in thyroid cancer patients, the level of NIS expression cannot precisely predict therapeutic outcome in some patients. In this research, we showed various apoptotic responses induced by 131 I in CMV-NIS (shown in Figure 2C , right). We also compared 131 I uptake from two different NIS-expressing tumors (one with high NIS and one with low NIS) and apoptosis imaging using ApoFlamma. From the analysis of ApoFlamma imaging in this study, the population of apoptotic cells in high NIS-expressing cells (CMV-NIS) was about 55% after 131 I treatment in vitro. In low NIS-expressing cells NIS activity in NIS-expressing tumors was monitored with gamma camera imaging before 131 I therapy. It was reported that 99m Tc, 125 I, 131 I, and rhenium 188 ( 188 Re) share the same uptake mechanism through NIS protein, and uptake imaging signals of 99m Tc and other radionuclides in the gamma camera imaging were highly correlated between cell numbers, which can be used as an indicator of NIS activity. 23 A correlation between NIS activity and apoptosis was observed.
In this research, radioisotope uptake by NIS and apoptosis in the course of 131 I therapy was also compared to tumor reduction (shown in Figure 4 ). Through radioisotope uptake and apoptosis imaging at an early time point (3 days) after therapy, the therapeutic effect of 131 I treatment could be predicted much earlier than analyzing tumor size reduction, which can only be clearly monitored 3 weeks after therapy. However, tumor reduction was more correlated with apoptosis than radioisotope uptake through NIS. Therefore, apoptosis imaging by ApoFlamma can provide useful information to predict the therapeutic response to 131 I treatment at an early stage of tumor therapy, allowing consideration of other treatment options for nonresponders. Evaluation of cell death through apoptosis is important to predict the precise therapeutic effects of 131 I treatment, 24, 25 and these less responding or nonresponding tumors for 131 I require additional therapeutic strategies, such as combination therapy including chemotherapy and radiotherapy. 3, 5, 26 Standard protocols for thyroidectomized patients should wait for at least 6 months to know the therapeutic response of 131 I therapy. 5 In this regard, if it is possible to predict the therapeutic effect of 131 I at an early stage of therapy, physicians have more time to prepare additional therapeutic options for nonresponding or less responding patients.
Limitations do exist in the current study. Apoptosis imaging using ApoFlamma cannot distinguish apoptotic cells and necrotic cells. ApoFlamma could be targeting histone H1 on the membrane of apoptotic cells and histone H1 in the nucleus of necrotic cells. 27 In contrast to apoptosis, necrosis evokes a strong inflammatory response and sometimes results in more aggressive tumors due to the stimulatory role of inflammation on tumor growth. 28 Alternatively, apoptosis is safe cell death as it does not cause an increase in toxic substances or local inflammation. Therefore, the ApoFlamma signal sometimes does not represent net apoptosis as a true indicator of successful therapy. In this regard, an efficient method is still required to be developed to distinguish between necrosis and apoptosis for evaluating the therapeutic response. 29 Another limitation of the study is in vivo application of fluorescent dye for imaging. Due to the limited tissue penetration depth of light for fluorescent dye, the fluorescent signal was used only for in vivo imaging. However, many near-infrared fluorescent dyes with improved penetration depth and a high signal to background ratio have recently been developed. 30 Since ApoFlamma used FPR-648 fluorescent dye and emits a relatively longer wavelength, our system could successfully demonstrate 131 I-mediated apoptosis in the NIS-expressing tumors in vivo. Successful radioisotope labeling was also reported, and both can be applied to overcome the limitation of fluorescence imaging. 27 
Conclusion
In this study, apoptosis imaging using ApoFlamma visualized successful apoptosis induced by 131 SUPPLEMENTARY MATERIAL Figure S1 . Diagram of binding ApoFlamma in apoptotic cells. ApoFlamma is a fluorescent dye (FPR-648) conjugated probe for apoptosis using histone H1 targeting peptide (ApoPep-1), which consists of six amino acids (CQRPQR). ApoFlamma binds to histone H1 exposed on the surface of apoptotic cell membrane and shows efficient tissue penetration and rapid clearance with low immunogenicity. Figure S2 . Comparison of apoptosis imaging between the ApoFlamma and annexin V administration on 131 I-treated tumor tissue (CMV-NIS). ApoFlamma and annexin V-fluorescein isothiocyanate (FITC) were performed to the tumor tissues 3 days after 131 I treatment (1.6 mCi). ApoFlamma targets nuclear membrane-localized histone H1, and annexin V targets phosphatidylserine at the inner membrane of cells.
